Molecular monitoring of chronic myeloid leukemia

Branford, 1999, Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics, Br J Haematol, 107, 587, 10.1046/j.1365-2141.1999.01749.x

Branford, 2002, High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance, Blood, 99, 3472, 10.1182/blood.V99.9.3472

Buchdunger, 1996, Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative, Cancer Res, 56, 100

Bustin, 2000, Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays, J Mol Endocrinol, 25, 169, 10.1677/jme.0.0250169

Bustin, 2002, Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): Trends and problems, J Mol Endocrinol, 29, 23, 10.1677/jme.0.0290023

Cross, 1993, Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation, Blood, 82, 1929, 10.1182/blood.V82.6.1929.1929

Daley, 1990, Induction of chronic myelogenous leukaemia in mice by the P210BCR-ABL gene of the Philadelphia chromosome, Science, 247, 824, 10.1126/science.2406902

Druker, 2001, Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia, N Engl J Med, 344, 1031, 10.1056/NEJM200104053441401

Druker, 1996, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nat Med, 2, 561, 10.1038/nm0596-561

Elefanty, 1990, bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice, EMBO J, 9, 1069, 10.1002/j.1460-2075.1990.tb08212.x

Goldman, 2001, Chronic myeloid leukemia: Current treatment options, Blood, 98, 2039, 10.1182/blood.V98.7.2039

Gorre, 2001, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification, Science, 293, 876, 10.1126/science.1062538

Hochhaus, 1996, Quantitative molecular methods to monitor the response of CML patients to interferon-alpha, Bone Marrow Transplant, 17, S41

Hochhaus, 1995, Variable numbers of Bcr-Abl transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha, Br J Haematol, 91, 126, 10.1111/j.1365-2141.1995.tb05257.x

Hochhaus, 2000, Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: Low levels of minimal residual disease are associated with continuing remission, Blood, 95, 62, 10.1182/blood.V95.1.62

Kantarjian, 2002, Hemtologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia, N Engl J Med, 346, 645, 10.1056/NEJMoa011573

Kelliher, 1990, Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR-ABL, Proc Natl Acad Sci USA, 87, 6649, 10.1073/pnas.87.17.6649

Kurzrock, 1998, Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity, J Clin Oncol, 16, 1526, 10.1200/JCO.1998.16.4.1526

Lin, 1996, Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation, Blood, 87, 4473, 10.1182/blood.V87.10.4473.bloodjournal87104473

Lion, 1995, Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon, Leukemia, 9, 1353

Mensink, 1998, Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR, Br J Haematol, 102, 768, 10.1046/j.1365-2141.1998.00823.x

Merx, 2002, Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha, Leukemia, 9, 1579, 10.1038/sj.leu.2402680

Morley, 1998, Quantifying leukemia, N Engl J Med, 339, 627, 10.1056/NEJM199808273390911

O'Brien, 2003, The IRIS study: International randomized study of Interferon and low-dose Ara-C versus STI571 (imatinib) in patients with newly-diagnosed chronic phase chronic myeloid leukemia, N Engl J Med, 348, 994, 10.1056/NEJMoa022457

Olavarria, 2001, Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia, Blood, 97, 1560, 10.1182/blood.V97.6.1560

Preudhomme, 1999, Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a “real time” quantitative RT-PCR assay, Leukemia, 13, 957, 10.1038/sj.leu.2401426

Radich, 2001, The significance of bcr-abl molecular detection in chronic myeloid leukemia patients “late,” 18 months or more after transplantation, Blood, 98, 1701, 10.1182/blood.V98.6.1701

Saussele, 2000, Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes, Leukemia, 14, 2006, 10.1038/sj.leu.2401929

Schoch, 2002, Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: A study on 350 cases, Leukemia, 16, 53, 10.1038/sj.leu.2402329

Shah, 2002, Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia, Cancer Cell, 2, 117, 10.1016/S1535-6108(02)00096-X

Stentoft, 2001, Kinetics of Bcr-Abl fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction, Eur J Haematol, 67, 302, 10.1034/j.1600-0609.2001.00556.x

Talpaz, 2002, Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study, Blood, 99, 1928, 10.1182/blood.V99.6.1928

Wang, 2002, Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia, Br J Haematol, 118, 771, 10.1046/j.1365-2141.2002.03705.x

Wang, 2001, Chronic myelogenous leukemia: laboratory diagnosis and monitoring, Genes Chromosomes Cancer, 32, 97, 10.1002/gcc.1171

Westgard, 1981, A multi-rule Shewart chart for quality control in clinical chemistry, Clin Chem, 27, 493, 10.1093/clinchem/27.3.493